A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation

• Published in: International journal of hematology Vol. 115; no. 1; pp. 69 - 76
• Main Authors: Izumi, Akihiko, Tachibana, Takayoshi, Ando, Taiki, Tanaka, Masatsugu, Kanamori, Heiwa, Nakajima, Hideaki
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.01.2022; Springer Nature B.V
• Subjects: Acute lymphoblastic leukemia; Adolescent; Adult; Chemotherapy; Complications; Disease-Free Survival; Female; Hematology; Hematopoietic Stem Cell Transplantation - adverse effects; Hepatic Veno-Occlusive Disease - etiology; Humans; Inotuzumab Ozogamicin - therapeutic use; Leukemia; Lymphatic leukemia; Male; Medicine; Medicine & Public Health; Middle Aged; Minimal residual disease; Monoclonal antibodies; Oncology; Original Article; Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy; Recurrence; Remission; Remission (Medicine); Remission Induction; Retrospective Studies; Salvage Therapy - methods; Stem cell transplantation; Survival; Targeted cancer therapy; Transplantation; Transplantation, Homologous - adverse effects; Treatment Outcome; Veno-occlusive disease; Young Adult; Acute lymphoblastic leukemia; Transplantation; Inotuzumab ozogamicin

This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27 years) treated between Ju...